A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon

Fattovich, Giovanna; Giustina, G.; Favarato, S.; Ruol, A

doi:10.1016/s0168-8278(96)80184-x

Cited by 459 publications

(219 citation statements)

References 21 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…83,84 Because IFN acts in part by stimulating the immune response, autoimmune side effects including hyperthyroidism, psoriasis, vitiligo, immune thrombocytopenia, and autoimmune hepatitis have been observed in susceptible individuals. 85,86 In the transplant setting, IFN may also lead to both acute and chronic graft rejection. This has been observed with high frequency in patients with renal allografts.…”

Section: Toxicities Associated With Interferonmentioning

confidence: 99%

Controversies in the management of hepatitis C virus infection after liver transplantation

Shiffman¹,

Vargas²,

Everson³

2003

Liver Transplantation

View full text Add to dashboard Cite

Recurrence of hepatitis C virus infection after liver transplantation is universal. A significant percentage of these patients develop progressive graft injury and cirrhosis. Those factors that modulate disease progression in liver transplant recipients with recurrent hepatitis C virus infection remain controversial and are poorly understood. Treatment of recurrent hepatitis C virus after liver transplantation with either interferon or interferon and ribavirin has yielded only limited success. Regardless of this, treatment is instituted. Peginterferon is more effective than standard interferon for treatment of chronic hepatitis C virus infection in the nontransplantation setting when used either alone or with ribavirin. The effectiveness of peginterferon, both with and without ribavirin in the posttransplantation setting, is currently being explored. In this review those factors thought to affect disease progression in patients with recurrent hepatitis C virus will be discussed, strategies that have been used to treat recurrent hepatitis C virus will be reviewed, and the impact that peginterferon may have on hepatitis C virus infection in the pretransplantation and posttransplantation setting will be explored. C irrhosis secondary to chronic infection with the hepatitis C virus (HCV) is the leading indication for liver transplantation. 1,2 Although transplantation is an effective treatment for end-stage liver disease secondary to chronic HCV infection, virus recurs in essentially all patients. 1-3 Progressive graft injury leading to cirrhosis occurs in about 25% to 33% of patients within just 5 years. [4][5][6][7][8] In addition, a limited group of patients (about 1% to 5% of recipients) develop rapidly progressive cholestatic hepatitis and liver failure within just 1 to 2 years. [8][9][10][11] Numerous studies have attempted to identify those factors that affect disease progression in these patients. Unfortunately, nearly all studies in this area have been retrospective in nature, conducted in patient populations of limited size, at single centers, utilized an array of immune suppressive medications in an uncontrolled manner, and have failed to consistently utilize protocol liver biopsy to investigate histologic progression. In addition, allograft rejection has not been either universally defined or treated and assays to measure serum HCV RNA have varied between centers and changed over time. As a result, data from many studies seem to contradict each other and the interpretation of these findings has varied widely. It is therefore not surprising how little progress has been made in our understanding of recurrent HCV over the past decade and that no universally accepted algorithm for managing these patients has emerged.Interferon (IFN) alfa with or without ribavirin (RBV) is the treatment of choice for patients with chronic HCV infection. 12,13 These medications have also been used to treat recurrent HCV after liver transplantation, but the interpretation of these data has been plagued by a similar set of limit...

show abstract

Section: Toxicities Associated With Interferonmentioning

confidence: 99%

Controversies in the management of hepatitis C virus infection after liver transplantation

Shiffman¹,

Vargas²,

Everson³

2003

Liver Transplantation

View full text Add to dashboard Cite

show abstract

“…All of these can compromise the therapeutic response to the treatment. In some cases depression can be so severe that patients experience suicidal ideation, and some published case-reports describe patients who have committed suicide (Ademmer et al, 2001, Dieperink et al, 2004, Fattovich et al, 1996, Fukunishi et al, 1998, Janssen et al, 1994. Effective and timely detection of depression is therefore important to ensure that appropriate treatment and support can be provided.…”

Section: Introductionmentioning

confidence: 99%

Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study

Hepgul

Kodate

Anderson

et al. 2012

International Journal of Nursing Studies

View full text Add to dashboard Cite

show abstract

“…Classical IFN-α has been correlated with the development of a variety of autoimmune disorders including Hashimoto thyroiditis, immune-mediated thrombocytopenia, hemolytic anemia, psoriasis, rheumatoid arthritis, systemic lupus-like syndromes, primary biliary cirrhosis and sarcoidosis. The reported cumulative incidence of all autoimmune disorders ranged from 1% to 3% [1,2] . Clinical thyroid disease has been reported to develop in 10%-15% of patients treated with IFN-α for CHC [3,4] .…”

Section: Introductionmentioning

confidence: 99%

Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C

Soultati¹

2007

WJG

View full text Add to dashboard Cite

Classical interferon-alpha has been shown to be correlated with the development of a variety of autoimmune disorders. A 38 year-old female patient developed simultaneously diabetic ketoacidosis and hyperthyroidism 5 mo following initiation of treatment with pegylated interferon-α and ribavirin for chronic hepatitis C. High titers of glutamic acid decarboxylase, antinuclear and thyroid (thyroid peroxidase and thyroglobulin) antibodies were detected. Antiviral treatment was withdrawn and the patient was treated with insulin for insulin-dependent diabetes mellitus and propranolol for hyperthyroidism. Twelve months after cessation of pegylated interferon-α therapy the patient was euthyroid without any medication but remained insulin-dependent.

show abstract

A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon

Cited by 459 publications

References 21 publications

Controversies in the management of hepatitis C virus infection after liver transplantation

Controversies in the management of hepatitis C virus infection after liver transplantation

Understanding clinical risk decision making regarding development of depression during interferon-alpha treatment for hepatitis-C: A qualitative interview study

Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C

Contact Info

Product

Resources

About